CymaBay Therapeutics Inc. (CBAY): Price and Financial Metrics

CymaBay Therapeutics Inc. (CBAY): $32.48

0.01 (+0.03%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add CBAY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#215 of 363

in industry

CBAY Price/Volume Stats

Current price $32.48 52-week high $32.50
Prev. close $32.47 52-week low $7.26
Day low $32.48 Volume 8,356,200
Day high $32.50 Avg. volume 4,113,430
50-day MA $28.59 Dividend yield N/A
200-day MA $18.42 Market Cap 3.73B

CBAY Stock Price Chart Interactive Chart >


CymaBay Therapeutics Inc. (CBAY) Company Bio


Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was founded in 1988 and is based in Newark, California.


CBAY Latest News Stream


Event/Time News Detail
Loading, please wait...

CBAY Latest Social Stream


Loading social stream, please wait...

View Full CBAY Social Stream

Latest CBAY News From Around the Web

Below are the latest news stories about CYMABAY THERAPEUTICS INC that investors may wish to consider to help them evaluate CBAY as an investment opportunity.

Why CymaBay Morphed From Dollar Stock To Biotech Rocket

CymaBay is sprinting to the finish line with a treatment for a serious liver disease and CBAY stock is on a massive run.

Yahoo | December 28, 2023

Industry Analysts Just Upgraded Their CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Revenue Forecasts By 32%

Celebrations may be in order for CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) shareholders, with the analysts delivering...

Yahoo | December 20, 2023

Insider Sell Alert: CymaBay Therapeutics Inc's President of R&D Charles Mcwherter Sells ...

In a recent transaction on December 18, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,332 shares of the company's stock.

Yahoo | December 19, 2023

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to four employees on December 15, 2023 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualif

Yahoo | December 18, 2023

Vice President Daniel Menold Sells 21,497 Shares of CymaBay Therapeutics Inc (CBAY)

In a recent transaction on December 15, 2023, Daniel Menold, the Vice President of Finance at CymaBay Therapeutics Inc, sold 21,497 shares of the company's stock.

Yahoo | December 16, 2023

Read More 'CBAY' Stories Here

CBAY Price Returns

1-mo N/A
3-mo 39.40%
6-mo 115.53%
1-year 214.12%
3-year 631.53%
5-year 155.35%
YTD 37.51%
2023 276.71%
2022 85.50%
2021 -41.11%
2020 192.86%
2019 -75.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!